ABL1 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ABL1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain AFF1 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 5 clinical trials for double-hit lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 39 clinical trials for double-hit lymphoma, of which 32 are open and 7 are closed. Of the trials that contain BCL2 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (9 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (12 open), 3 are phase 2/phase 3 (2 open), and 4 are phase 3 (4 open) [3].

BCL6 is an inclusion eligibility criterion in 37 clinical trials for double-hit lymphoma, of which 31 are open and 6 are closed. Of the trials that contain BCL6 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 11 are phase 1 (9 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (12 open), 3 are phase 2/phase 3 (2 open), and 3 are phase 3 (3 open) [3].

BCR is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain BCR status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

CBFB is an inclusion eligibility criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain CBFB status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

CD274 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain DEK status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ELL status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain FLT3 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

KIT is an inclusion eligibility criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain KIT status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 5 clinical trials for double-hit lymphoma, of which 3 are open and 2 are closed. Of the trials that contain KMT2A status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (1 open), and 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MECOM status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MLLT1 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MLLT10 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MLLT3 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MLLT4 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 39 clinical trials for double-hit lymphoma, of which 32 are open and 7 are closed. Of the trials that contain MYC status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (9 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (12 open), 3 are phase 2/phase 3 (2 open), and 4 are phase 3 (4 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain MYH11 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain NRIP3 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain NUP214 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain RPN1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain RUNX1 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain RUNX1T1 status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain TP53 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [3].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].